We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Study Links Nicotine with Breast Cancer Growth and Metastasis

By LabMedica International staff writers
Posted on 30 Oct 2008
New research suggests a possible role for nicotine in breast tumor development and metastases. More...


The study, conducted by researchers at the Beth Israel Deaconess Medical Center (Boston, MA, USA), is among the first to examine the effects of nicotine on mammary cells. "Although numerous studies indicate the role of nicotine exposure in tumor promotion, little is known about the effect of nicotine on breast tumor development, especially on the metastatic process of breast cancer,” said lead author Chang Yan Chen, Ph.D., M.D., from Beth Israel Deaconess Medical Center.

Through a series of in vitro experiments, Dr. Chen and her team of researchers determined that breast epithelial-like MCF10A cells and cancerous MCF7 cells both express several subunits of nAChR (nicotine receptor), that when bound, initiate a signaling process, potentially increasing cell growth and migration.

"The best known role of nAChR is in the nerve system,” Dr. Chen noted. "Although cells from various tissue origins express different subunits of nAChR, we know very little about the functions of nAChR in non-neuronal cells and tissues, in particular in mammary cells. We were able to determine that mammary cells express different subunits of nAChR and that nicotine, possibly through perturbing cell cycle checkpoints, potentiates tumorigenesis in mammary cancer-prone or cancer cells.”

In vivo studies confirmed these findings. When injected into the tail of a mouse, the cancerous MCF7 cells migrated to the lungs. From in vivo and in vitro studies, it indicates that nicotine is not a conventional carcinogen, but rather it combines with other yet to be determined factors to enable tumorigenesis. "In vitro and in vivo tests showed that no metastasis occurs when the administration of nicotine alone,” said Dr. Chen. "At this point, we can only suggest that nicotine potentiates the growth-related process.”

Dr. Chen hopes to conduct more studies, in particular under the genetic backgrounds with loss or defect of different tumor suppressors, to additionally explore the effects of nicotine in relation to first- and second-hand exposure, on breast cancer initiation and development.

The study was published in the October 1, 2008, issue of the journal Cancer Research.

Related Links:
Beth Israel Deaconess Medical Center



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.